Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395656 | 0.93 | FFAR1 (0.39) | RAB9AFFAR1LPAR1HDAC1HDAC6 | |
| SCHEMBL5401812 | 0.92 | LTB4R (0.43) | FFAR1PTGDR2KMT2AALDH1A1POLB | |
| SCHEMBL5397151 | 0.90 | FFAR1 (0.46) | FFAR1LPAR1KMT2AALDH1A1LPAR5 | |
| SCHEMBL5403476 | 0.89 | FFAR1 (0.41) | FFAR1KMT2AALDH1A1MEN1POLB | |
| SCHEMBL5406332 | 0.88 | RAF1 (0.46) | KMT2AALDH1A1MEN1MAPTTHRB | |
| SCHEMBL5401600 | 0.87 | RAB9A (0.43) | RAB9ALPAR1PTGDR2HDAC1HDAC6 | |
| SCHEMBL5397700 | 0.86 | MAPK8 (0.43) | RAB9AFFAR1KMT2AALDH1A1AOC3 | |
| SCHEMBL5394588 | 0.85 | POLB (0.43) | KMT2AALDH1A1MEN1POLBMAPT | |
| SCHEMBL5398708 | 0.85 | POLB (0.47) | KMT2AALDH1A1MEN1POLBMAPT | |
| SCHEMBL5403373 | 0.84 | ABCB1 (0.43) | RAB9ALPAR1PTGDR2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | RAB9A 3132/4885FFAR1 65/4885LPAR1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.